A Refractory Celiac Patient Successfully Treated With Mesenchymal Stem Cell Infusions

Area of Science:

• Gastroenterology
• Immunology
• Regenerative Medicine

Background:

• Type II refractory celiac disease (RCD) is a severe malabsorption disorder with no effective treatment.
• Mesenchymal stem cells (MSCs) possess regenerative and immunomodulatory properties.
• Investigating autologous bone marrow-derived MSCs for RCD type II feasibility, safety, and efficacy.

Observation:

• A 51-year-old woman with RCD type II received serial MSC infusions.
• MSC isolation, expansion, and characterization followed standard protocols.
• Patient underwent 4 systemic infusions of 2 x 10(6) MSCs/kg body weight, 4 months apart, with no adverse effects.

Findings:

• Gradual and durable amelioration of the patient's general condition observed.
• Normalization of malabsorption indexes, stool frequency, BMI, and laboratory results.
• Mucosal architecture improved, and aberrant intraepithelial lymphocytes decreased.
• Expression of Interleukin-15 (IL-15) and its receptor significantly reduced.

Implications:

• Serial MSC infusions represent a promising therapeutic strategy for RCD type II.
• This treatment potentially leads to recovery from a life-threatening condition.
• Blocking the IL-15 pathogenic pathway is key to the observed therapeutic effects.